Background <p>Neoadjuvant chemoimmunotherapy (NACI) shows promise for locally advanced cervical cancer (LACC), but drug-tolerant persister (DTP) cells and immunosuppressive microenvironmental adaptations limit clinical efficacy. The underlying determinants governing heterogeneous responses to NACI regimens remain poorly understood, particularly regarding how dynamic tumor-immune interactions shape therapeutic outcomes.</p> Methods <p>We characterized microenvironmental dynamics in patients with LACC by integrating single-cell RNA sequencing (RNA-seq),…
Oligoclonal tumor-specific CD8 T-cell revival and IRE1{alpha}/XBP1-GDF15-mediated immunosuppressive niches determine neoadjuvant chemoimmunotherapy efficacy in cervical cancer
Journal for ImmunoTherapy of Cancer | | Cao, G., Wang, Y., Zeng, H., Zhi, Y., Guo, Y., Xu, M., Ruan, Y., Wang, Y., Xiao, Y., Lu, J., Tse, K. Y., Gao, J., Zhang, Q., Wang, C., Han, Z., Li, F.
Topics: blood-cancer, cervical-cancer, immunotherapy, chemotherapy
Read the full article at Journal for ImmunoTherapy of Cancer